[1] | Mengying ZHU, Ping YU, Guohong GE, Yuqi MA, Xiling FU, Jiabao CHANG. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous direct-acting antiviral agent failure[J]. Journal of Clinical Hepatology, 2024, 40(11): 2201-2204. doi: 10.12449/JCH241112 |
[2] | Rongjiong ZHENG, Xiaobo LU. Low-level viremia in chronic hepatitis B patients treated with first-line treatment with nucleos(t)ide analogues and its treatment strategies[J]. Journal of Clinical Hepatology, 2024, 40(5): 880-883. doi: 10.12449/JCH240506 |
[3] | Yang WANG, Hao LIAO, Zhongping DENG, Jing ZHAO, Dandan BIAN, Yan REN, Yingying JIANG, Shuang LIU, Yu CHEN, Fengmin LU, Zhongping DUAN, Sujun ZHENG. Value of combined baseline serum HBV markers in predicting HBeAg seroconversion in chronic hepatitis B patients treated by nucleos(t)ide analogues[J]. Journal of Clinical Hepatology, 2023, 39(5): 1070-1075. doi: 10.3969/j.issn.1001-5256.2023.05.011 |
[4] | Fengming LU, Bo FENG, Sujun ZHENG, Suzhen JIANG, Ruifeng YANG, Junliang FU, Dong JI, Shuangsuo DANG, Xiaobo LU, Hongsong CHEN, Xinyue CHEN, Hong REN, Zhiliang GAO, Yuemin NAN, Xiaoyuan XU, Junqi NIU, Wenhong ZHANG, Hui ZHUANG. Current status of the research on low-level viremia in chronic hepatitis B patients receiving nucleos(t)ide analogues[J]. Journal of Clinical Hepatology, 2021, 37(6): 1268-1274. doi: 10.3969/j.issn.1001-5256.2021.06.007 |
[5] | Zhou YouQian, Li Cui, Yin FengMing, Zhang HaiYan, Ren Bin, Yang Wei. Change in HBsAg quantification after HBV DNA negative conversion in chronic hepatitis B patients treated with nucleos (t) ide analogues[J]. Journal of Clinical Hepatology, 2019, 35(5): 977-981. doi: 10.3969/j.issn.1001-5256.2019.05.009 |
[6] | Hong ShengZhen, Xu Jie. Effect of entecavir versus tenofovir disoproxil fumarate antiviral therapy in reducing the risk of hepatocellular carcinoma in patients with chronic hepatitis B: Reflections on a Korean retrospective study[J]. Journal of Clinical Hepatology, 2019, 35(4): 734-736. doi: 10.3969/j.issn.1001-5256.2019.04.007 |
[7] | Yuan Ling, Ceng BaiMei, Lin ShiDe. Research advances in the pathogenesis and diagnosis/treatment of muscle injury after treatment with nucleos (t) ide analogues in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2019, 35(3): 627-630. doi: 10.3969/j.issn.1001-5256.2019.03.039 |
[8] | Ruan JianWen, Gao LiJuan, Su RuKai, Wang YaJiao, Yang Jing. Clinical effect of nucleos (t) ide analogues in treatment of acute exacerbation of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2019, 35(6): 1251-1255. doi: 10.3969/j.issn.1001-5256.2019.06.014 |
[9] | Wu Di, Huang Da, Ning Qin. New strategies for clinical cure and Institute of hepatitis B:viral suppression combined with immune modulation and its road map[J]. Journal of Clinical Hepatology, 2018, 34(5): 919-925. doi: 10.3969/j.issn.1001-5256.2018.05.002 |
[10] | Chen Lu, Xie Qing. How to evaluate combination therapy using interferon and nucleos(t)ide analogues[J]. Journal of Clinical Hepatology, 2016, 32(11): 2050-2053. doi: 10.3969/j.issn.1001-5256.2016.11.006 |
[11] | Zhong ChunXiu, Cai ShaoHang, Yin JunHua, Gao YuLin. Impact of nucleos(t)ide analogues on quality of life in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(11): 2080-2083. doi: 10.3969/j.issn.1001-5256.2016.11.013 |
[12] | Ning Ling, Sun Jian, Chen Nan, Hou JinLin. Renal safety in chronic hepatitis B patients treated with nucleos(t) ide analogues[J]. Journal of Clinical Hepatology, 2016, 32(5): 981-985. doi: 10.3969/j.issn.1001-5256.2016.05.042 |
[13] | Chen HeMin, Shao GuoHui. Criteria for withdrawal of nucleos( t) ide analogues and their clinical significance in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(7): 1283-1286. doi: 10.3969/j.issn.1001-5256.2016.07.013 |
[14] | Xu Yong, Feng JiHong. Effects of nucleos(t) ide analogues on estimated glomerular filtration rate and serum creatinine level in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(2): 279-283. doi: 10.3969/j.issn.1001-5256.2016.02.016 |
[15] | Fan Xiu, Lin XiaoDong, Cen XiaoHong, Hou YuXiang. Research advances in drug resistance to nucleos( t) ide analogues in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(4): 611-613. doi: 10.3969/j.issn.1001-5256.2015.04.033 |
[16] | Yu YiQi, Chen ShaoLong, Zhang WenHong. Research progress in combination therapy with pegylated interferon and nucleos(t)ide analogues in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(9): 1513-1519. doi: 10.3969/j.issn.1001-5256.2015.09.039 |
[17] | Li Qiang, Zhuo QiBin, Huang YuXian, Li XinYan, Chen Liang. Combination therapy and sequential therapy with interferons and nucleos( t) ide analogues against HBV[J]. Journal of Clinical Hepatology, 2015, 31(4): 495-499. doi: 10.3969/j.issn.1001-5256.2015.04.005 |
[18] | Ren Shuang, Zhang Hua, Hu XinCai, Liu Ping. Meta-analysis of the clinical efficacy of combination therapy with traditional Chinese medicine and nucleoside analogue antiviral drugs for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(4): 264-269+275. |
[19] | Wang LiPing, Han FangZheng, Li ChunYang, Yan Mei, Zhang YanChao, Yan XueBing. Evaluation of adefovir primary resistance and adefovir repulsive mutations of the HBV DNA P gene in chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2012, 28(8): 606-608. |
[20] | Zhu YuCheng, Gao YuJin, Yan JiaHui. Severe hepatitis resulted from inappropriate use of nucleoside drugs[J]. Journal of Clinical Hepatology, 2010, 26(6): 596-597. |